Half of the patients with primary hyperparathyroidisms have a vitamin D deficiency: Aggravating the osseous attack;La moitié des patients atteints d'hyperparathyroïdies primaires ont un déficit en vitamine D aggravant l'atteinte osseuse

Presse Medicale

Volumn 40, Issue 2, 2011, Pages

  Velayoudom Cephise, Fritz Line ^a,b   Foucan, Lydia ^b   Soudan, Benoît ^a   Cardot Bauters, Catherine ^a   Vantyghem, Marie Christine ^a   D'herbomez, Michèle ^a   Tison Muchery, Françoise ^a   Wemeau, Jean Louis ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CHU de Pointe a Pitre   (Guadeloupe)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ARTICLE; BONE DENSITY; BONE FRAGILITY; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CALCIUM URINE LEVEL; CONTROLLED STUDY; DISEASE EXACERBATION; HUMAN; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS; PREVALENCE; PRIMARY HYPERPARATHYROIDISM; PROSPECTIVE STUDY; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 79551512028     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2010.08.005     Document Type: Article

References (33)

1. Albright F. A page out of the history of hyperparathyroidism. J. Clin Endocrinol Metab 1948, 8:637-657.
2. Cope O. The study of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med 1966, 274:1174-1182.
3. Silverberg S.J., Shane E., de la Cruz L., Dempster D.W., Feldman F., Seldin D., et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989, 4:283-291.
4. Christiansen P., Steiniche T., Brixen K., Hessov I., Melsen F., Charles P., et al. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone 1997, 21:93-99.
5. Fraser W.D. Hyperparathyroidism. Lancet 2009, 374:145-158.
6. Bilezikian J.P., Potts Jr.J.T. Asymptomatic primary hyperparathyroidism: new issues and new questions - bridging the past with the future. J Bone Miner Res 2002, 17(Suppl. 2). [N57-67].
7. Nordenström E., Westerdahl J., Lindergård B., Lindblom P., Bergenfelz A. Multifactorial risk profile for bone fractures in primary hyperparathyroidism. World J Surg 2002, 26:1463-1467.
8. Briot K., Audran M., Cortet B., Fardellone P., Marcelli M., Orcel P., et al. Vitamine D: effets osseux et extra-osseux ; recommandations de bon usage. Presse Med 2009, 38:43-54.
9. Souberbielle J.-C., Prié D., Courbebaisse M., Friedlander G., Houillier P., Maruani G., et al. Actualité sur les effets de la vitamine D et l'évaluation du statut vitaminique D. Ann Endocrinol 2008, 69:501-510.
10. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001, 22:477-501.
11. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-268.
12. Meyer H.E., Falch J.A., Søgaard A.J., Haug E. Vitamin D deficiency and secondary hyperparathyroidism and the association with bone mineral density in persons with Pakistani and Norwegian background living in Oslo, Norway. The Oslo Health Study. Bone 2004, 35:412-417.
13. Lumb G.A., Stanbury S.W. Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am J Med 1974, 56:833-839.
14. Silverberg S., Shane E., Dempster D., Bilezikian J. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 1999, 107:561-567.
15. Bandeira F., Caldas G., Freese E., Griz L., Faria M., Bandeira C. Relationship between serum vitamin d status and clinical manifestations of primary hyperparathyroidism. Endocr Pract 2002, 8:266-270.
16. Boudou P., Ibrahim F., Cormier C., Sarfati E., Souberbielle J.C. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 2006, 29:511-515.
17. Clements M.R., Davies M., Fraser D.R., Lumb G.A., Mawer E.B., Adams P.H. Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci (Lond) 1987, 73:659-664.
18. Clements M.R., Davies M., Hayes M.E., Hickey C.D., Lumb G.A., Mawer E.B., et al. The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf) 1992, 37:17-27.
19. Carnevale V., Manfredi G., Romagnoli E., De Geronimo S., Paglia F., Pepe J., et al. Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage?. Clin Endocrinol (Oxf) 2004, 60:81-86.
20. Rao D.S., Agarwal G., Talpos G.B., Phillips E.R., Bandeira F., Mishra S.K. Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 2002, 17(Suppl. 2):N75-80.
21. Raef H., Ingemansson S., Sobhi S., Sultan A., Ahmed M., Chaudhry M. The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region. J Endocrinol Invest 2004, 27:807-812.
22. Ozbey N., Erbil Y., Ademoĝlu E., Ozarmaĝan S., Barbaros U., Bozbora A. Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J Surg 2006, 30:321-326.
23. Grey A.B., Stapleton J.P., Evans M.C., Reid I.R. Accelerated bone loss in post-menopausal women with mild primary hyperparathyroidism. Clin Endocrinol (Oxf) 1996, 44:697-702.
24. Bilezikian J.P., Meng X., Shi Y., Silverberg S.J. Primary hyperparathyroidism in women: a tale of two cities - New York and Beijing. Int J Fertil Womens Med 2000, 45:158-165.
25. Bussey A.D., Bruder J.M. Urinary calcium excretion in primary hyperparathyroidism: relationship to 25-hydroxyvitamin d status. Endocr Pract 2005, 11:37-42.
26. Calzada-Nocaudie M., Chanson P., Conte-Devolx B., Delemer B., Estour B., Henry J.F., et al. Prise en charge de l'hyperparathyroïdie primaire asymptomatique: consensus d'experts de la SFE. Ann Endocrinol 2006, 67:7-12.
27. Bilezikian J.P., Khan A.A., Potts Jr.J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab 2009, 94:335-339. on behalf of the Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism.
28. Feldman D. Vitamin D, parathyroid hormone, and calcium: a complex regulatory network. Am J Med 1999, 107:637-639.
29. Kantorovich V., Gacad M.A., Seeger L.L., Adams J.S. Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. J Clin Endocrinol Metab 2000, 85:3541-3543.
30. Tucci J.R. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol 2009, 161:189-193.
31. Stewart Z.A., Blackford A., Somervell H., Friedman K., Garrett-Mayer E., Dackiw A.P., et al. 25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery 2005, 138:1018-1025.
32. Grubbs E.G., Rafeeq S., Jimenez C., Feng L., Lee J.E., Evans D.B., et al. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial?. Surgery 2008, 144:852-858.
33. Van Doorn L., Lips P., Netelenbos J.C., Hackeng W.H. Bone histomorphometry and serum concentrations of intact parathyroid hormone (PTH (1-84)) in patients with primary hyperparathyroidism. Bone Miner 1993, 23:233-242.